Functional sequence for silencing circular RNA h-hsacirc005838, lentiviral vector and application of lentiviral vector
By constructing shRNA1 lentiviral vector and viral packaging, the problem of low overexpression efficiency and difficult specific silencing of lentiviral vector when silencing circular RNA h-hsa_circ_005838 is solved, and efficient silencing and stable transfection effect is achieved, which is suitable for breast cancer diagnosis.
Patent Information
- Application Number
- CN202510559164.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-30
- Publication Date
- 2025-07-22
AI Technical Summary
Existing lentiviral vectors have problems of low overexpression efficiency and difficult specific silencing when silencing circular RNA h-hsa_circ_005838. Traditional linear expression vectors are difficult to simulate circular structures, and the siRNA or shRNA design is complex and there is a risk of off-targeting.
A shRNA1 lentiviral vector was designed, and the interfering target sequence siRNA1 was obtained by targeting the circular gene of interest RNA h-hsa_circ_005838, the single-stranded oligo1 sequence was synthesized and annealed, and attached to the linearized pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO vector to construct shRNA1 lentiviral vector, and viral packaging was used using pSPAX2 and pMD2G plasmids to form a lentiviral packaging titer kit.
It realizes efficient silencing of circular RNA h-hsa_circ_005838, has a stable transfection effect, can continuously inhibit target gene expression, avoiding the inconvenience caused by low plasmid transfection efficiency, and is suitable for breast cancer diagnosis.
Smart Images

Figure CN120350005A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of genetic engineering, and particularly relates to a functional sequence for silencing circular RNA h-hsa_circ_005838, a lentiviral vector, and their applications. Background Art
[0002] Lentivirus vectors are gene therapy vectors developed based on HIV-1 (human immunodeficiency virus type 1). They have the advantages of a wide infection spectrum, can effectively infect dividing and quiescent cells, and can stably express foreign genes for a long time. Therefore, they have become important tools for gene therapy and molecular diagnosis. Now the lentivirus system has been widely applied to gene overexpression, RNA interference, microRNA research in various cell lines, and in vivo animal experiments. However, in circRNA-related research, the design of lentiviral vectors faces unique challenges: circular structure interference, traditional linear expression vectors are difficult to simulate the closed circular structure of circRNA, resulting in low overexpression efficiency; specific silencing is difficult, and the technical route for designing small interfering RNA (siRNA) or short hairpin RNA (shRNA) targeting the back-splicing site of circRNA is complex and there is a risk of off-target. Therefore, developing an adapted and efficient lentiviral vector system for silencing corresponding circRNA and establishing a reliable detection method based on this is the key to promoting its clinical translation. Summary of the Invention
[0003] The object of the present invention is to provide a functional sequence for silencing circular RNA h-hsa_circ_005838, a lentiviral vector, and their applications in preparing a kit for breast cancer diagnosis, wherein the functional sequence shRNA1 can directly and efficiently infect cells and silence the circular RNA h-hsa_circ_005838 sequence.
[0004] To achieve the above object of the invention, the present invention provides the following technical solutions:
[0005] The present invention provides a functional sequence for silencing circular RNA h-hsa_circ_005838, the functional sequence being shRNA1, the shRNA1 including a sense strand and an antisense strand, the sequence of the sense strand being as shown in SEQ ID NO:4, and the sequence of the antisense strand being as shown in SEQ ID NO:5.
[0006] The present invention provides a lentiviral vector of shRNA1, which is constructed using the functional sequence shRNA1.
[0007] The present invention also provides a construction method of the lentiviral vector of shRNA1, including the following steps:
[0008] (1) The interfering target sequence siRNA1 was obtained for the circular target gene RNAh-hsa_circ_005838, and the single-stranded oligo1 sequence was designed and synthesized using the interfering target sequence siRNA1, and then annealed to obtain the functional sequence shRNA1 described in claim 1.
[0009] (2) The linearized vector obtained after digestion was ligated with the functional sequence shRNA1 described in step (1) to obtain the shRNA1 lentiviral vector.
[0010] Preferably, the sequence of the interfering target sequence siRNA1 described in step (1) is as shown in SEQ ID NO:2; the single-stranded oligo1 sequence includes the single-stranded oligo1-1 sequence and the single-stranded oligo1-2 sequence.
[0011] Preferably, the reaction system for the annealing described in step (1) includes 2 μL of 10*oligo Buffer, 1 μL of the single-stranded oligo1-1 sequence, 1 μL of the single-stranded oligo1-2 sequence, and 16 μL of H2O.
[0012] Preferably, the annealing program includes: 95°C for 10 min; 75°C for 10 min; 55°C for 10 min; 35°C for 10 min; 15°C for 10 min.
[0013] Preferably, the enzymes used in the digestion process in step (2) are the restriction endonucleases BamHI and EcoRI.
[0014] Preferably, the original vector for the digestion treatment is the pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO vector.
[0015] Preferably, after the ligation reaction in step (2), it further includes transforming the obtained ligation product into the competent cell DH5α for culture, and then identifying positive clones by colony PCR and performing sequencing.
[0016] The present invention also provides a lentivirus packaging titer kit, which includes the above shRNA1 lentiviral vector, virus packaging auxiliary plasmids, and transfection reagent, and the virus packaging auxiliary plasmids include the pSPAX2 plasmid and the pMD2G plasmid.
[0017] Preferably, the mass ratio of the shRNA1 lentiviral vector, the pSPAX2 plasmid, and the pMD2G plasmid is (8-12):10:5.
[0018] Preferably, the ratio of the total mass of the shRNA1 lentiviral vector, pSPAX2 plasmid and pMD2G plasmid to the volume of the transfection reagent is (23 - 27) μg: 75 μL.
[0019] The present invention also provides the use of the functional sequence, or the shRNA1 lentiviral vector, or the shRNA1 lentiviral vector obtained by the construction method in the preparation of a kit for breast cancer diagnosis.
[0020] By adopting the above technical solutions, the present invention has the following beneficial effects:
[0021] In the present invention, the interference target sequence siRNA1 is obtained for the circular target gene RNAh-hsa_circ_005838, and then the single-stranded oligo1 sequence is designed and synthesized using the interference target sequence siRNA1. After annealing, the functional sequence shRNA1 is finally obtained. The functional sequence shRNA1 and the shRNA1 lentiviral vector can directly and efficiently infect cells and silence the circular RNAh-hsa_circ_005838 sequence. The transfection effect is stable, and the expression of the target gene can be continuously inhibited in cells; at the same time, various inconveniences caused by low plasmid transfection efficiency can be avoided. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 It is a simple construction process diagram of the shRNA1 lentiviral vector of the present invention;
[0023] Figure 2 It is a structural diagram of the pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO vector;
[0024] Figure 3 It is the sequencing result of the positive clone vector screened by the present invention (the green area is the part matching the target sequence);
[0025] Figure 4 It is a flow chart of lentivirus packaging and quality detection of the present invention;
[0026] Figure 5 For the cell proliferation and cell viability of each treatment group ( Figure 5 in which A represents cell viability and B represents cell proliferation);
[0027] Figure 6 For the cell cycle of each treatment group ( Figure 6 in which A represents the cell cycle distribution map of CAL51 cells, B represents the cell cycle distribution map of CALDOX cells, C represents the cell cycle distribution map of MDA-MB-231 cells, D represents the cell cycle distribution map of MDA-MB-231 / ADR cells, and E represents the cell cycle distribution statistical chart);
[0028] Figure 7 To detect the apoptosis of cells in each treatment group by flow cytometry ( Figure 7 In which, A represents the staining map and B represents the statistical chart);
[0029] Figure 8 To observe the clone formation ability of cells in each treatment group by soft agar cloning experiment ( Figure 8 In which, A represents the staining map and B represents the statistical chart);
[0030] Figure 9 To observe the results of cell migration ability by Transwell experiment ( Figure 9 In which, A represents the staining map and B represents the statistical chart);
[0031] Figure 10 To observe the results of cell invasion ability by Transwell experiment ( Figure 10 In which, A represents the staining map and B represents the statistical chart);
[0032] Figure 11 To observe the results of cell migration ability by scratch experiment ( Figure 11 In which, A represents the scratch imaging map and B represents the statistical chart). Specific implementation mode
[0033] The present invention provides a functional sequence for silencing circular RNA h-hsa_circ_005838. The functional sequence is shRNA1. The shRNA1 includes a sense strand and an antisense strand. The sequence of the sense strand is as shown in SEQ ID NO:4, and the specific sequence is GATCCGCAGAGAGTTCAGGACAGATTGATTCTCGAGAATCAATCTGTCCTGAACTCTCTGCTTTT TTG; the sequence of the antisense strand is as shown in SEQ ID NO:5, and the specific sequence is AATTCAAAAAAGCAGAGAGTTCAGGACAGATTGATTCTCGAGAATCAATCTGTCCTGAACTCTC TGCG.
[0034] In the present invention, the sequence of the circular RNA h-hsa_circ_005838 is as shown in SEQ ID NO: 1,The specific sequence is GACAGATTGATTCACTTTGGAGCTGTAAGTACTGATGTATTAGGGTGCAGCGCTCATTGTTCCTTGACGCAGAGTCCCAAAATGAATATCCAAGAGCAGGGTTTCCCCTTGGACCTCGGAGCAAGTTTCACCGAAGATGCTCCCCGACCCCCAGTGCCTGGTGAGGAGGGAGAACTGGTGTCCACAGACCCGAGGCCCGCCAGCTACAGTTTCTGCTCCGGGAAAGGTGTTGGCATTAAAGGTGAGACTTCGACGGCCACTCCGAGGCGCTCGGATCTGGACCTGGGGTATGAGCCTGAGGGCAGTGCCTCCCCCACCCCACCATACTTGAAGTGGGCTGAGTCACTGCATTCCCTGCTGGATGACCAAGATGGGATAAGCCTGTTCAGGACTTTCCTGAAGCAGGAGGGCTGTGCCGACTTGCTGGACTTCTGGTTTGCCTGCACTGGCTTCAGGAAGCTGGAGCCCTGTGACTCGAACGAGGAGAAGAGGCTGAAGCTGGCGAGAGCCATCTACCGAAAGTACATTCTTGATAACAATGGCATCGTGTCCCGGCAGACCAAGCCAGCCACCAAGAGCTTCATAAAGGGCTGCATCATGAAGCAGCTGATCGATCCTGCCATGTTTGACCAGGCCCAGACCGAAATCCAGGCCACTATGGAGGAAAACACCTATCCCTCCTTCCTTAAGTCTGATATTTATTTGGAATATACGAGGACAGGCTCGGAGAGCCCCAAAGTCTGTAGTGACCAGAGCTCTGGGTCAGGGACAGGGAAGGGCATATCTGGATACCTGCCGACCTTAAATGAAGATGAGGAATGGAAGTGTGACCAGGACATGGATGAGGACGATGGCAGAGACGCTGCTCCCCCCGGAAGACTCCCTCAGAAGCTGCTCCTGGAGACAGCTGCCCCGAGGGTCTCCTCCAGTAGACGGTACAGCGAAGGCAGAGAGTTCAG。,
[0035] The present invention also provides a shRNA1 lentiviral vector, which is constructed by using the functional sequence shRNA1.
[0036] The present invention also provides a method for constructing the shRNA1 lentiviral vector, comprising the following steps:
[0037] (1) Obtain the interference target sequence siRNA1 for the circular target gene RNAh-hsa_circ_005838, design and synthesize the single-stranded oligo1 sequence by using the interference target sequence siRNA1, and then anneal to obtain the functional sequence shRNA1 as described in claim 1.
[0038] (2) Perform a ligation reaction on the linearized vector obtained after enzyme digestion and the functional sequence shRNA1 in step (1) to obtain the shRNA1 lentiviral vector.
[0039] In the present invention, the sequence of the interference target sequence siRNA1 in step (1) is as shown in SEQ ID NO:2, and the specific sequence is GCAGAGAGTTCAGGACAGATTGATT; the single-stranded oligo1 sequence includes the single-stranded oligo1-1 sequence and the single-stranded oligo1-2 sequence, and the single-stranded oligo1-1 sequence (i.e., the sense strand of shRNA1) is as shown in SEQ ID NO:4; the single-stranded oligo1-2 sequence (i.e., the antisense strand of shRNA1) is as shown in SEQ ID NO:5.
[0040] In the present invention, the reaction system for annealing in step (1) includes 2 μL of 10*oligo Buffer, 1 μL of the single-stranded oligo1-1 sequence, 1 μL of the single-stranded oligo1-2 sequence, and 16 μL of H2O.
[0041] In the present invention, the annealing program in step (1) includes: 95°C for 10 min; 75°C for 10 min; 55°C for 10 min; 35°C for 10 min; 15°C for 10 min.
[0042] In the present invention, the enzymes used in the enzyme digestion process are the restriction endonucleases BamHI and EcoRI.
[0043] In the present invention, the original vector for enzyme digestion is the pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO vector.
[0044] In the present invention, after the enzyme digestion treatment, agarose gel electrophoresis is performed, and the purified linearized vector is recovered.
[0045] In the present invention, after performing a ligation reaction on the linearized vector and the annealed product, a ligation product is obtained. Preferably, the ligation product is transformed into competent cells DH5α, cultured with shaking at 37 °C and 230 rpm for 45 - 60 min, the resulting bacterial solution is spread onto a solid plate with the corresponding resistance, and cultured in an incubator at 37 °C for 12 - 16 h; then single colonies are selected for colony verification, and positive clones are selected for sequencing.
[0046] The present invention also provides a lentivirus packaging titer kit, comprising the shRNA1 lentiviral vector, a viral packaging auxiliary plasmid, and a transfection reagent.
[0047] In the present invention, the viral packaging auxiliary plasmid includes the pSPAX2 plasmid and the pMD2G plasmid, and the transfection reagent is preferably Lipofiter TM Transfection reagent. The mass ratio of the shRNA1 lentiviral vector, the PAX2 plasmid, and the pMD2G plasmid of the present invention is preferably (8 - 12):10:5, more preferably (9 - 11):10:5, and even more preferably 10:10:5; the proportional relationship between the total mass of the shRNA1 lentiviral vector, the pSPAX2 plasmid, and the pMD2G plasmid and the volume of the transfection reagent is preferably (23 - 27) μg:75 μL, more preferably (24 - 26) μg:75 μL, and even more preferably 25 μg:75 μL.
[0048] The present invention also provides the use of the functional sequence shRNA1, or the shRNA1 lentiviral vector, or the shRNA1 lentiviral vector obtained by the construction method in the preparation of a kit for breast cancer diagnosis.
[0049] The technical solutions provided by the present invention will be described in detail below with reference to the examples, but they should not be construed as limiting the protection scope of the present invention.
[0050] Example 1 (1)
[0052] Design interference targets for the target gene circular RNA h-hsa_circ_005838. The sequence of the target gene circular RNA h-hsa_circ_005838 is shown in SEQ ID NO: 1,The specific sequence is GACAGATTGATTCACTTTGGAGCTGTAAGTACTGATGTATTAGGGTGCAGCGCTCATTGTTCCTTGACGCAGAGTCCCAAAATGAATATCCAAGAGCAGGGTTTCCCCTTGGACCTCGGAGCAAGTTTCACCGAAGATGCTCCCCGACCCCCAGTGCCTGGTGAGGAGGGAGAACTGGTGTCCACAGACCCGAGGCCCGCCAGCTACAGTTTCTGCTCCGGGAAAGGTGTTGGCATTAAAGGTGAGACTTCGACGGCCACTCCGAGGCGCTCGGATCTGGACCTGGGGTATGAGCCTGAGGGCAGTGCCTCCCCCACCCCACCATACTTGAAGTGGGCTGAGTCACTGCATTCCCTGCTGGATGACCAAGATGGGATAAGCCTGTTCAGGACTTTCCTGAAGCAGGAGGGCTGTGCCGACTTGCTGGACTTCTGGTTTGCCTGCACTGGCTTCAGGAAGCTGGAGCCCTGTGACTCGAACGAGGAGAAGAGGCTGAAGCTGGCGAGAGCCATCTACCGAAAGTACATTCTTGATAACAATGGCATCGTGTCCCGGCAGACCAAGCCAGCCACCAAGAGCTTCATAAAGGGCTGCATCATGAAGCAGCTGATCGATCCTGCCATGTTTGACCAGGCCCAGACCGAAATCCAGGCCACTATGGAGGAAAACACCTATCCCTCCTTCCTTAAGTCTGATATTTATTTGGAATATACGAGGACAGGCTCGGAGAGCCCCAAAGTCTGTAGTGACCAGAGCTCTGGGTCAGGGACAGGGAAGGGCATATCTGGATACCTGCCGACCTTAAATGAAGATGAGGAATGGAAGTGTGACCAGGACATGGATGAGGACGATGGCAGAGACGCTGCTCCCCCCGGAAGACTCCCTCAGAAGCTGCTCCTGGAGACAGCTGCCCCGAGGGTCTCCTCCAGTAGACGGTACAGCGAAGGCAGAGAGTTCAG. The interfering target sequence siRNA1 was designed at the circularization interface of the target gene.The siRNA1 sequence is as shown in SEQ ID NO:2, and the specific sequence is GCAGAGAGTTCAGGACAGATTGATT. Meanwhile, an interfering sequence was designed for the control viral vector, and the designed control interfering target sequence siRNA was obtained. The siRNA sequence is as shown in SEQ ID NO:3, and the specific sequence is GCAGAGAGTTCAGGACAGATTGATT.,
[0053] The single-stranded DNA oligo1 sequence and the control single-stranded DNA oligo sequence (synthesized by Hanheng Biotechnology (Shanghai) Co., Ltd.) were designed and synthesized respectively using the above-obtained interfering target sequence siRNA1 and the control interfering target sequence siRNA. The single-stranded DNA oligo1 sequence and the control single-stranded DNA oligo sequence were purified by PAGE. The single-stranded DNA oligo1 sequence includes the single-stranded oligo1-1 sequence (i.e., the sense strand of shRNA1) and the single-stranded oligo1-2 sequence (the antisense strand of shRNA1). The single-stranded oligo1-1 sequence is as shown in SEQ ID NO:4, and the specific sequence is GATCCGCAGAGAGTTCAGGACAGATTGATTCTCGAGAATCAATCTGTCCTGAACTCTCTGCTTTT TTG; the single-stranded oligo1-2 sequence is as shown in SEQ ID NO:5, and the specific sequence is AATTCAAAAAAGCAGAGAGTTCAGGACAGATTGATTCTCGAGAATCAATCTGTCCTGAACTCTC TGCG. The control single-stranded DNA oligo sequence includes the single-stranded oligo-1 sequence (i.e., the sense strand of shRNA) and the single-stranded oligo-2 sequence (the antisense strand of shRNA). The single-stranded oligo-1 sequence is as shown in SEQ ID NO:6, and the specific sequence is GATCCGTTCTCCGAACGTGTCACGTAATTCAAGAGATTACGTGACACGTTCGGAGAATTTTTTC; the single-stranded oligo-2 sequence is as shown in SEQ ID NO:7, and the specific sequence is AATTGAAAAAATTCTCCGAACGTGTCACGTAATCTCTTGAATTACGTGACACGTTCGGAGAACG.
[0054] The above-obtained single-stranded DNA oligo1 sequence and the control single-stranded DNA oligo sequence were annealed respectively to obtain the double-stranded DNA oligo1 sequence with sticky ends (i.e., the shRNA1 sequence) and the control double-stranded DNA oligo sequence (i.e., the control shRNA sequence). The annealing system is shown in Table 1, and the annealing program is shown in Table 2.
[0055] Table 1 Annealing System Composition
[0056]
[0057] Table 2 Annealing Program
[0058] (2)
[0060] Select the pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO vector as the original vector. Use the restriction enzymes BamHI and EcoRI to perform double digestion on the original vector. Add each reagent in the order shown in Table 3 to prepare a 40 μL vector digestion system, then gently pipette and mix well, and place it in a 37 °C water bath for 1 - 2 h to obtain the vector digestion product. Perform agarose gel electrophoresis on the vector digestion product, recover the target band, linearize it, and react at 37 °C for 1 h, then cut the gel to recover the target fragment. The electrophoresis result indicates that the linearized vector construction is successful.
[0061] Table 3 Vector Digestion System
[0062] (3)
[0064] Connect the prepared shRNA1 sequence and the control shRNA sequence to the vector digestion product respectively. The ligation reaction system is shown in Table 4, and ligate at 22 °C for 1 - 2 h, or ligate overnight at 16 °C. That is, the linearized vector is ligated to the double-stranded DNA of the shRNA1 sequence (or the control shRNA sequence) to obtain the ligation product.
[0065] Table 4 Ligation Reaction System
[0066] (4)
[0068] After taking out the Escherichia coli DH5α competent cells (purchased from Tiangen, product number CB101-03) from the -80 °C refrigerator, immediately place them on ice to melt. The operation during the aliquoting of the competent cells should be gentle to reduce mechanical damage to them. After the competent cells are melted, aliquot them at a volume of 50 μL per tube. After aliquoting, add the ligation product in an amount of 1 / 10 of the volume of the competent cells and place it on ice for 20 - 30 min. Heat shock at 42 °C for 90 s, immediately insert it on ice after heat shock, and incubate on ice for 2 - 3 min. In the laminar flow hood, add 500 μL of antibiotic-free LB medium and gently invert it up and down 3 - 5 times. Then incubate it at 37 °C and 230 rpm for 45 - 60 min. Spread the bacterial solution on the solid plate with the corresponding resistance, spread it evenly, and then place it in a 37 °C incubator for 12 - 16 h to obtain the transformed competent cell bacterial solution.
[0069] Use the transformed competent cell bacterial solution as a template, design primer sequences, and perform colony PCR identification experiments. The primer sequences are Primer 1-F and Primer 1-R. The sequence of Primer 1-F is as shown in SEQ ID NO:8, and the specific sequence is GGACTATCATATGCTTACCG; the sequence of Primer 1-R is as shown in SEQ ID NO:9, and the specific sequence is GTCCCTATTGGCGTTACTATG.
[0070] The colony PCR identification system is shown in Table 5, and the colony PCR identification procedure is shown in Table 6.
[0071] Table 5 Colony PCR Identification System
[0072]
[0073] Table 6 Colony PCR Identification Procedure
[0074]
[0075]
[0076]
[0077] The sequencing results showed that (such as Figure 3 ): If the sequencing results are consistent with the target sequence, the construction of the target plasmid is successful.
[0078] The competent cell bacterial solution after transformation of the positive clone with correct sequencing was subjected to plasmid extraction and purification. The plasmid extraction operation was carried out according to the instructions of the extraction kit (purchased from Tiangen, product number DP117). The extracted plasmid was used for cell transfection after passing the QC verification.
[0079] Example 2 Lentivirus packaging
[0080] Twenty-four hours before transfection, trypsin (purchased from Thermo, product number LP0042) was used to digest 293T cells (purchased from the Chinese Academy of Sciences) in the logarithmic growth phase, which were inoculated into DMEM growth medium containing 10% FBS and cultured in an incubator at 37 °C and 5% CO2. Transfection could be carried out when the cell density reached a confluence rate of 70-80%. The cell medium was replaced with serum-free medium 2 hours before transfection.
[0081] 10 μg of shRNA1 lentiviral vector, 10 μg of pSPAX2 plasmid, 5 μg of pMD2G plasmid and 75 μL of LipofiterT M transfection reagent (purchased from Hanheng Biotechnology (Shanghai) Co., Ltd.) were mixed evenly and then incubated at room temperature for 15 min to obtain the transfection system. Then the transfection system was slowly added dropwise to 293T cells and cultured in a cell incubator at 37 °C and 5% CO2. The fresh complete medium containing 10% fetal bovine serum (FBS) was replaced 16 hours after transfection.
[0082] The virus supernatants were collected twice at 48 h and 72 h after transfection (fresh complete medium was replaced after collection at 48 h). When collecting the virus at 48 h, the medium in the 100 mm dish was poured into a 50 mL centrifuge tube, taking care not to let the culture dish wall touch the centrifuge tube mouth to prevent bacterial contamination. Then 10 mL of fresh complete medium containing 10% fetal bovine serum (FBS) was added and the dish was placed in a constant temperature incubator at 37 °C and 5% CO2 for continued culture. When collecting the virus at 72 h, the medium in the 100 mm dish was directly poured into a 50 mL centrifuge tube, also taking care not to let the culture dish wall touch the centrifuge tube mouth to prevent bacterial contamination. The virus supernatant in the 50 mL centrifuge tube was centrifuged at 4 °C and 2000×g for 10 min to remove cell debris; then the virus stock supernatant was collected and placed in an ultracentrifuge tube, centrifuged at 4 °C and 82700×g for 120 min, and the virus pellet was resuspended with complete medium. Finally, the ultracentrifugation resuspension was aliquoted into sterilized virus tubes. The virus was aliquoted as required and stored in an -80 °C refrigerator. The flow chart of lentivirus packaging is as Figure 4as shown
[0083] Example 3 Lentivirus Quality Detection
[0084] (I) Sterility Test
[0085] Detection method: Take 10 μL of the virus and add it to Hela cells (purchased from the Chinese Academy of Sciences) in a 96-well plate for verification. After culturing for 24 h, examine under a microscope.
[0086] QC standard: The culture medium should be clear and transparent, there should be no obvious particles in the cell gaps, and there should be no contamination by any bacteria or fungi.
[0087] The detection results show that: there are no obvious particles in the Hela cell gaps, and there is no contamination by any bacteria or fungi.
[0088] (II) Titer Detection
[0089] Digest and count the 293T cells in good growth state and then dilute them to 1×10 5 / mL, add them to a 96-well plate, 100 μL / well, and prepare 6 wells for each virus. Place them in an incubator at 37 °C and 5% CO2 for culture. On the second day, prepare 6 1.5-mL EP tubes. Add 10 μL of the virus solution to the first EP tube, and then perform a 3-fold serial dilution, with a total of 6 dilution factors. On the third day, for the wells that need to be screened with puromycin, first aspirate 100 μL of the virus-containing culture medium, and add 100 μL of 10% FBS complete medium containing 1.5 μg / mL puromycin. On the fifth day, observe the results under a fluorescence microscope. 6 h before observing the results, replace the fresh 10% FBS complete medium. Aspirate 80 μL of the culture medium from the wells, and then add 80 μL of fresh 10% FBS complete medium. Place them in an incubator at 37 °C and 5% CO2 for culture. Observe the results under a fluorescence microscope after 6 h. Calculate the virus titer for the wells with a fluorescence or live cell percentage of 10 - 50%.
[0090] Titer (TU / mL) = number of cells × percentage of positive clones × MOI × virus dilution factor × 10 3
[0091] In this experiment, the MOI value is 1, the number of cells is 4×10 4 , the virus dilution factor is 30, the percentage of positive clones of LV-h-hsa_circ_005838shRNA1-ZsGreen-PURO is 25%, and the titer is 3×10 8 TU / mL; the percentage of positive clones of the LV-ZsGreen-PURO NC control is 12.5%, and the titer is 1.5×10 8 TU / mL.
[0092] Example 4: Detecting the effect of circAXIN1 on the phenotypes of TNBC cells
[0093] To study the biological function of circAXIN1 (h-hsa_circ_0005838) in TNBC cells (triple-negative breast cancer), the effects on the phenotypes of TNBC cells were detected after silencing or overexpressing circAXIN1.
[0094] Hanheng Biotechnology (Shanghai) Co., Ltd. was commissioned to design and construct an overexpression vector for circAXIN1, and then it was divided into a control group (plCDH-ciR) and an overexpression experimental group (circAXIN1). Among them, the plCDH-ciR group was transfected with the circAXIN1 overexpression vector in doxorubicin-sensitive CAL51 cells (purchased from the Cell Bank of the Chinese Academy of Sciences); the circAXIN1 group was transfected with the circAXIN1 overexpression vector in doxorubicin-sensitive MDA-MB-231 cells (purchased from Tianjin Cosmo Biotechnology Co., Ltd.).
[0095] The above shRNA1 lentiviral vector was used to silence circAXIN1, which was divided into a control group (si-NC) and a silencing experimental group (si-circAXIN1). Among them, the si-NC group silenced circAXIN1 in doxorubicin-resistant CALDOX cells; the si-circAXIN1 group silenced circAXIN1 in doxorubicin-resistant MDA-MB-231 / ADR cells (purchased from Tianjin Cosmo Biotechnology Co., Ltd.).
[0096] The changes in cell phenotypes after overexpressing and silencing circAXIN1 were observed. The methods for cell phenotype indicators included: CCK8 to detect cell proliferation and cell viability, flow cytometry to detect cell cycle and apoptosis, soft agar colony formation assay to observe colony formation ability, scratch assay to observe cell migration ability, and Transwell assay to observe cell invasion ability and cell migration ability.
[0097] The results showed that overexpression of circAXIN1 could increase cell viability (such as Figure 5 ); the number of cells in the S-phase distribution increased (such as Figure 6 ); the apoptosis rate of cells decreased (such as Figure 7 ); the colony formation ability of cells was enhanced (such as Figure 8 ); the cell migration and invasion abilities (such as Figure 9 and Figure 10 ) were significantly increased, which was consistent with the results of the scratch assay (such as Figure 11 ). Silencing circAXIN1, on the other hand, would yield the opposite results.
[0098] In summary, it can be seen that the technical solution of the present invention obtains the interfering target sequence siRNA1 for the circular target gene RNAh-hsa_circ_005838, and then the finally obtained functional sequence shRNA1 can directly and efficiently infect cells and silence the circular RNA h-hsa_circ_005838 sequence, and the transfection effect is stable.
[0099] The above are only the preferred embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention.
Claims
1. A functional sequence of the silencing circular RNA h-hsa_circ_005838, characterized in that, The functional sequence is shRNA1, which includes a sense strand and an antisense strand. The sequence of the sense strand is as shown in SEQ ID NO:4, and the sequence of the antisense strand is as shown in SEQ ID NO:
5.
2. A shRNA1 lentiviral vector, characterized in that, It is constructed using the functional sequence shRNA1 described in claim 1.
3. The construction method of the shRNA1 lentiviral vector according to claim 2, characterized in that, It includes the following steps: (1) Obtain the interfering target sequence siRNA1 for the circular target gene RNAh-hsa_circ_005838, design and synthesize the single-stranded oligo1 sequence using the interfering target sequence siRNA1, and then anneal to obtain the functional sequence shRNA1 described in claim 1. (2) Perform a ligation reaction on the linearized vector obtained after enzyme digestion and the functional sequence shRNA1 in step (1) to obtain the shRNA1 lentiviral vector.
4. The construction method according to claim 3, characterized in that, The sequence of the interfering target sequence siRNA1 in step (1) is as shown in SEQ ID NO:2; the single-stranded oligo1 sequence includes the single-stranded oligo1-1 sequence and the single-stranded oligo1-2 sequence.
5. The construction method according to claim 4, wherein The reaction system for the annealing in step (1) includes 2 μL of 10*oligo1Buffer, 1 μL of the single-stranded oligo1-1 sequence, 1 μL of the single-stranded oligo1-2 sequence, and 16 μL of H2O. The annealing program includes: 95°C for 10 min; 75°C for 10 min; 55°C for 10 min; 35°C for 10 min; 15°C for 10 min.
6. The construction method according to claim 3, characterized in that, The enzymes used in the enzyme digestion process in step (2) are the restriction endonucleases BamHI and EcoRI. The original vector for enzyme digestion is the pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO vector.
7. The construction method according to claim 3, characterized in that, After the ligation reaction in step (2), it further includes transforming the obtained ligation product into competent cells DH5α for culture, and then identifying positive clones by colony PCR and performing sequencing.
8. A lentivirus packaging titer kit, characterized in that, It contains the shRNA1 lentiviral vector described in claim 2, viral packaging auxiliary plasmids, and transfection reagents. The viral packaging auxiliary plasmids include the pSPAX2 plasmid and the pMD2G plasmid.
9. The lentivirus packaging titer kit according to claim 8, characterized in that The mass ratio of the shRNA1 lentiviral vector, pSPAX2 plasmid, and pMD2G plasmid described in claim 2 is (8-12):10:
5. The proportional relationship between the total mass of the shRNA1 lentiviral vector, pSPAX2 plasmid, and pMD2G plasmid and the volume of the transfection reagent is (23-27) μg:75 μL.
10. Use of the functional sequence described in claim 1, or the shRNA1 lentiviral vector described in claim 2, or the shRNA1 lentiviral vector obtained by the construction method according to any one of claims 3-7 in the preparation of a kit for breast cancer diagnosis.
Citation Information
Cited By
Kit for breast cancer diagnosis and application thereof
CN121878214A
SiRNA (small interfering Ribonucleic Acid), shRNA (short hairpin Ribonucleic Acid) and lentiviral vector of targeted silencing hsacirc007800 and application of siRNA, shRNA and lentiviral vector
CN122326603A
